Role of insulin-like growth factor-II mRNA-binding protein-3 in invadopodia formation and the growth of oral squamous cell carcinoma in athymic nude mice

Head and Neck

Volumn 34, Issue 9, 2012, Pages 1329-1339

  Hwang, Young Sun ^a   Park, Kwang Kyun ^a,b   Cha, In Ho ^a   Kim, Jin ^a,b   Chung, Won Yoon ^a,b  

^a Yonsei University College of Dentistry   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

insulin like growth factor II mRNA binding protein 3; invadopodia; matrix degradation; MMPs; oral squamous cell carcinoma

Indexed keywords

CORTACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; F ACTIN; GELATINASE A; GELATINASE B; SOMATOMEDIN BINDING PROTEIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; DOWN REGULATION; EXTRACELLULAR MATRIX; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELLS, CULTURED; EXTRACELLULAR MATRIX; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MICE; MICE, NUDE; MOUTH NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865019059     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21929     Document Type: Article

References (68)

1. Weaver AM,. Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis 2006; 23: 97-105. (Pubitemid 44440169)
2. Caldieri G, Ayala I, Attanasio F, Buccione R,. Cell and molecular biology of invadopodia. Int Rev Cell Mol Biol 2009; 275: 1-34.
3. Yilmaz M, Christofori G,. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
4. Yamaguchi H, Lorenz M, Kempiak S, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 2005; 168: 441-452. (Pubitemid 40205066)
5. Ross AF, Oleynikov Y, Kislauskis EH, et al. Characterization of a beta-actin mRNA zipcode-binding protein. Mol Cell Biol 1997; 17: 2158-2165. (Pubitemid 27133302)
6. Deshler JO, Highett MI, Abramson T, Schnapp BJ,. A highly conserved RNA-binding protein for cytoplasmic mRNA localization in vertebrates. Curr Biol 1998; 8: 489-496. (Pubitemid 28203068)
7. Havin L, Git A, Elisha Z, et al. RNA-binding protein conserved in both microtubule- and microfilament-based RNA localization. Genes Dev 1998; 12: 1593-1598. (Pubitemid 28299511)
8. Runge S, Nielsen FC, Nielsen J, et al. H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. J Biol Chem 2000; 275: 29562-29569. (Pubitemid 32043834)
9. Doyle GA, Betz NA, Leeds PF, et al. The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 1998; 26: 5036-5044. (Pubitemid 28517556)
10. Liao B, Hu Y, Herrick DJ, Brewer G,. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005; 280: 18517-18524. (Pubitemid 41389102)
11. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262-1270. (Pubitemid 29046868)
12. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003; 88: 887-894. (Pubitemid 36520876)
13. Müeller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 1999; 88: 95-99. (Pubitemid 29467415)
14. Müeller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997; 14: 2729-2733. (Pubitemid 27283112)
15. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005; 29: 188-195. (Pubitemid 40170636)
16. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7: 556-564. (Pubitemid 43923666)
17. Hammer NA, Hansen TO, Byskov AG, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005; 130: 203-212. (Pubitemid 41149808)
18. Li C, Zota V, Woda BA, et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol 2007; 20: 1263-1268. (Pubitemid 350126850)
19. Jeng YM, Wang TH, Lu SH, et al. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg 2009; 96: 66-73.
20. Wagner M, Kunsch S, Duerschmied D, et al. Transgenic overexpression of the oncofetal RNA binding protein KOC leads to remodeling of the exocrine pancreas. Gastroenterology 2003; 124: 1901-1914. (Pubitemid 36666785)
21. Vikesaa J, Hansen TV, Jønson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-1468.
22. Bowden ET, Coopman PJ, Mueller SC,. Invadopodia: unique methods for measurement of extracellular matrix degradation in vitro. Methods Cell Biol 2001; 63: 613-627.
23. Kim KY, Kim J, Kim HJ, et al. A method for detecting significant genomic regions associated with oral squamous cell carcinoma using aCGH. Med Biol Eng Comput 2010; 48: 459-468.
24. Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF,. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog 2006; 45: 518-529.
25. Ludwig T,. Local proteolytic activity in tumor cell invasion and metastasis. Bioessays 2005; 27: 1181-1191. (Pubitemid 43076144)
26. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-5338.
27. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65. (Pubitemid 24216953)
28. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273: 871-880. (Pubitemid 28049179)
29. Christensen ME,. The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 1998; 45: 121-134. (Pubitemid 28183944)
30. Zimmermann M, Zouhair A, Azria D, Ozsahin M,. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006; 1: 11.
31. van Oijen MG, Rijksen G, ten Broek FW, Slootweg PJ,. Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J Oral Pathol Med 1998; 27: 147-152. (Pubitemid 28181101)
32. Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004; 64: 6166-6173. (Pubitemid 39129418)
33. Tague SE, Muralidharan V, D'souza-Schorey C,. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci U S A 2004; 101: 9671-9676. (Pubitemid 38869294)
34. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, et al. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res 2006; 66: 3034-3043.
35. Angers-Loustau A, Hering R, Werbowetski TE, et al. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2004; 2: 595-605. (Pubitemid 39557663)
36. Clark ES, Whigham AS, Yarbrough WG, Weaver AM,. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res 2007; 67: 4227-4235. (Pubitemid 46815069)
37. Vignjevic D, Montagnac G,. Reorganisation of the dendritic actin network during cancer cell migration and invasion. Semin Cancer Biol 2008; 18: 12-22. (Pubitemid 350266367)
38. Kelly T, Yan Y, Osborne RL, et al. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis 1998; 16: 501-512. (Pubitemid 29009586)
39. Rosenthal EL, Matrisian LM,. Matrix metalloproteases in head and neck cancer. Head Neck 2006; 28: 639-648. (Pubitemid 44025114)
40. Ayala I, Baldassarre M, Caldieri G, Buccione R,. Invadopodia: a guided tour. Eur J Cell Biol 2006; 85: 159-164.
41. Stetler-Stevenson WG, Hewitt R, Corcoran M,. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147-154. (Pubitemid 26179261)
42. Nakahara H, Howard L, Thompson EW, et al. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A 1997; 94: 7959-7964. (Pubitemid 27343757)
43. Coussens LM, Fingleton B, Matrisian LM,. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392. (Pubitemid 34270240)
44. Lehti K, Lohi J, Valtanen H, Keski-Oja J,. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J 1998; 334: 345-353. (Pubitemid 28448577)
45. Ellerbroek SM, Fishman DA, Kearns AS, et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 1999; 59: 1635-1641. (Pubitemid 29160137)
46. Stanton H, Gavrilovic J, Atkinson SJ, et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 1998; 111: 2789-2798. (Pubitemid 28479202)
47. Hiroshi Sato, Motoharu Seiki,. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor. J Biochem 1996; 119: 209-215.
48. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999; 99: 81-92. (Pubitemid 29468632)
49. Koshikawa N, Giannelli G, Cirulli V, et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-624.
50. d'Ortho MP, Will H, Atkinson S, et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-757. (Pubitemid 28022492)
51. Myoung H, Kim MJ, Lee JH, et al. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients. Int J Oral Maxillofac Surg 2006; 35: 1005-1010. (Pubitemid 44615441)
52. Timpson P, Wilson AS, Lehrbach GM, et al. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007; 67: 9304-9314. (Pubitemid 47535919)
53. Hui R, Ball JR, Macmillan RD, et al. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998; 17: 1053-1059. (Pubitemid 28425416)
54. Myllykangas S, Böhling T, Knuutila S,. Specificity, selection and significance of gene amplifications in cancer. Semin Cancer Biol 2007; 17: 42-55. (Pubitemid 46075192)
55. Schuuring E,. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 1995; 159: 83-96.
56. Wu H, Reynolds AB, Kanner SB, et al. Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Mol Cell Biol 1991; 11: 5113-5124. (Pubitemid 21895272)
57. Wu H, Parsons JT,. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 1993; 120: 1417-1426. (Pubitemid 23081688)
58. Uruno T, Liu J, Zhang P, et al. Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol 2001; 3: 259-266. (Pubitemid 32201321)
59. Weaver AM, Karginov AV, Kinley AW, et al. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol 2001; 11: 370-374. (Pubitemid 32200742)
60. Weaver AM,. Cortactin in tumor invasiveness. Cancer Lett 2008; 265: 157-166.
61. Clark ES, Weaver AM,. A new role for cortactin in invadopodia: regulation of protease secretion. Eur J Cell Biol 2008; 87: 581-590.
62. Nadal A, Cardesa A,. Molecular biology of laryngeal squamous cell carcinoma. Virchows Archiv 2003; 442: 1-7. (Pubitemid 36216353)
63. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF,. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925. (Pubitemid 37493640)
64. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584. (Pubitemid 23229640)
65. Khazaie K, Schirrmacher V, Lichtner RB,. EGF receptor in neoplasia and metastasis. Cancer Metast Rev 1993; 12: 255-274. (Pubitemid 23293284)
66. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356. (Pubitemid 36025259)
67. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-832. (Pubitemid 28280548)
68. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5: 4164-4174. (Pubitemid 30013801)